Eli Lilly and Company $LLY Shares Sold by South Dakota Investment Council

South Dakota Investment Council trimmed its stake in shares of Eli Lilly and Company (NYSE:LLY) by 0.9% in the second quarter, Holdings Channel reports. The fund owned 62,814 shares of the company’s stock after selling 557 shares during the period. Eli Lilly and Company accounts for about 0.9% of South Dakota Investment Council’s portfolio, making the stock its 12th biggest position. South Dakota Investment Council’s holdings in Eli Lilly and Company were worth $48,965,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. State of Michigan Retirement System raised its stake in shares of Eli Lilly and Company by 0.6% during the second quarter. State of Michigan Retirement System now owns 265,504 shares of the company’s stock worth $206,968,000 after purchasing an additional 1,700 shares during the last quarter. Carson Advisory Inc. increased its stake in Eli Lilly and Company by 4.0% in the 2nd quarter. Carson Advisory Inc. now owns 647 shares of the company’s stock valued at $504,000 after buying an additional 25 shares during the period. Nicholas Company Inc. raised its position in Eli Lilly and Company by 9.4% during the 2nd quarter. Nicholas Company Inc. now owns 92,014 shares of the company’s stock worth $71,728,000 after buying an additional 7,940 shares during the last quarter. Tredje AP fonden lifted its stake in shares of Eli Lilly and Company by 18.8% in the 2nd quarter. Tredje AP fonden now owns 304,733 shares of the company’s stock worth $237,549,000 after acquiring an additional 48,160 shares during the period. Finally, Eleva Capital SAS purchased a new stake in shares of Eli Lilly and Company in the second quarter valued at about $1,287,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 2.2%

LLY opened at $862.96 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a market cap of $816.76 billion, a price-to-earnings ratio of 56.40, a PEG ratio of 1.21 and a beta of 0.47. Eli Lilly and Company has a one year low of $623.78 and a one year high of $935.63. The business’s fifty day moving average is $780.74 and its two-hundred day moving average is $771.71.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter in the previous year, the company posted $1.18 EPS. The business’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be given a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is currently 39.22%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on LLY. Deutsche Bank Aktiengesellschaft lowered their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. BMO Capital Markets upped their price objective on Eli Lilly and Company from $840.00 to $930.00 and gave the stock an “outperform” rating in a report on Monday, October 20th. Daiwa America downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. UBS Group decreased their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Finally, Daiwa Capital Markets downgraded shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price target for the company. in a report on Sunday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $940.00.

Insider Buying and Selling at Eli Lilly and Company

In related news, Director J Erik Fyrwald purchased 1,565 shares of the company’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the transaction, the director owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This represents a 2.14% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gabrielle Sulzberger acquired 117 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders bought 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.